- Home
- GENB vs PENN Comparison
GENB vs PENN Comparison
Compare GENB & PENN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GENB | PENN |
|---|---|---|
| Founded | 2018 | 1972 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Hotels/Resorts |
| Sector | | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.7B |
| IPO Year | N/A | 1996 |
Fundamental Metrics
Financial Performance| Metric | GENB | PENN |
|---|---|---|
| Price | $12.25 | $14.47 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 15 |
| Target Price | N/A | ★ $20.14 |
| AVG Volume (30 Days) | 709.7K | ★ 4.4M |
| Earning Date | 05-03-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $6,362,900,000.00 |
| Revenue This Year | N/A | $6.62 |
| Revenue Next Year | N/A | $3.84 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $11.00 | $11.65 |
| 52 Week High | $13.95 | $20.61 |
Technical Indicators
Market Signals| Indicator | GENB | PENN |
|---|---|---|
| Relative Strength Index (RSI) | 47.80 | 53.59 |
| Support Level | $11.26 | $14.27 |
| Resistance Level | $13.70 | $15.36 |
| Average True Range (ATR) | 0.96 | 0.66 |
| MACD | -0.00 | -0.05 |
| Stochastic Oscillator | 39.81 | 40.74 |
Price Performance
Historical ComparisonAbout GENB Generate Biomedicines Inc. Common Stock
Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.
About PENN PENN Entertainment Inc.
Penn Entertainment's origins date back to its 1972 racetrack opening in Pennsylvania. Today, Penn operates 43 properties across 20 states and 12 brands, including Hollywood Casino and Ameristar. Land-based casinos represented 85% of total sales in 2024; 15% was from the interactive segment, which includes sports, iGaming, and media revenue. The retail portfolio generates mid-30s EBITDAR margins and helps position the company to obtain licenses for the digital wagering markets. Additionally, Penn's media asset, theScore, provides access to sports betting/iGaming technology and clientele, helping it form a leading digital position.